Jaids-Journal of Acquired Immune Deficiency Syndromes

Papers
(The H4-Index of Jaids-Journal of Acquired Immune Deficiency Syndromes is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Addressing Stigma by Increasing Empathy Toward Vulnerable Populations in Preprofessional Trainees: Impacts of the Generation Tomorrow Summer Health Disparities Scholars Program53
HIV and Aging in the Era of ART and COVID-1946
Effects of the COVID-19 Pandemic on ART Initiation and Access to HIV Viral Load Monitoring in Adults Living With HIV in West Africa: A Regression Discontinuity Analysis43
Follow-Up Outcomes of Children, Adolescents, and Young People on Darunavir-Based Third-Line Antiretroviral Therapy: Observational Cohort From 9 African Countries43
Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037)42
Outcomes of Lymphoma Patients Admitted to the ICU Are Not Influenced by HIV Status: A Retrospective, Observational Cohort Study41
Patterns of HIV Treatment Preferences Among People With Diverse Demographic, Social, and Behavioral Characteristics Who Are Living With HIV in the United States38
Breastfeeding Among Women Living With HIV in the Era of Lifelong ART: An Observational Multicountry Study in Eastern and Southern Africa37
Changing Patterns of Lymphoma in the Antiretroviral Therapy Era in Johannesburg, South Africa37
Late Re-Engagement Into HIV Care Among Adults in the Swiss HIV Cohort Study34
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week33
Trends in the Uptake of Index Testing Among Adolescents in USAID-Supported President's Emergency Plan for AIDS Relief Programs, October 2017–September 202232
Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine30
Using Data-To-Care Strategies to Optimize the HIV Care Continuum in Connecticut: Results From a Randomized Controlled Trial27
Cost and cost-effectiveness of online recruitment to increase HIV self-testing among Black and Hispanic/Latino men who have sex with men in the United States, 2020-202127
Markers of inflammation and immune dysfunction and non-AIDS cancer risk in adults with HIV27
Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials27
The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies26
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment25
Structural Equation Modeling of Stigma and HIV Prevention Clinical Services Among Transgender and Gender Diverse Adults: The Mediating Role of Substance Use and HIV Sexual Risk24
A Novel Method for Assessing Poor Quality of Life Among People With HIV24
Brief Report: Validation of the D:A:D Chronic Kidney Disease Risk Score Incorporating Proteinuria in People Living With HIV in Harare, Zimbabwe24
Clinical features and outcomes of mpox in people with and without HIV: a national comparative study24
Understanding Disparities in Antiretroviral Therapy Adherence and Sustained Viral Suppression Among Black, Hispanic/Latina, and White Women in the United States – Medical Monitoring Project, United St23
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial23
0.094225883483887